Comparison of the prophylactic anti-emetic efficacy of ramosetron and ondansetron in patients at high-risk for postoperative nausea and vomiting after total knee replacement.

Abstract

We compared the prophylactic anti-emetic efficacy of ramosetron, a newly developed 5-HT(3) antagonist, and ondansetron in patients at high-risk for postoperative nausea and vomiting after total knee replacement. Eighty-four patients with three risk factors for postoperative nausea and vomiting (female, non-smoking and use of postoperative opioid use (ropivacaine and hydromorphone patient controlled epidural analgesia)) undergoing unilateral total knee replacement were randomly allocated to ramosetron 0.3 mg (n = 42) or ondansetron 4 mg (n = 42) groups. A complete response (no postoperative nausea and vomiting and no rescue anti-emetic) and the incidence of postoperative nausea and vomiting were assessed for 48 h after surgery at 0-2 h, 2-6 h, 6-24 h, and 24-48 h. More patients in the ramosetron group had a complete response between 2 and 48 h. The incidence of nausea between 2 and 24 h and the severity of nausea between 2 and 48 h were also less in the ramosetron group. Ramosetron was more effective than ondansetron in preventing postoperative nausea and vomiting in patients at high risk undergoing unilateral total knee replacement.

• Authors: T S Hahm, Justin Sangwook Ko, S J Choi, M S Gwak
• Journal: Anaesthesia (Anaesthesia) Vol. 65 Issue 5 Pg. 500-4 (May 2010) ISSN: 1365-2044 [Electronic] England
• PMID: 20337618 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Antiemetics
• Benzimidazoles
• Ondansetron
• ramosetron

Topics

• Aged
• Aged, 80 and over
• Antiemetics (therapeutic use)
• Arthroplasty, Replacement, Knee
• Benzimidazoles (therapeutic use)
• Female
• Humans
• Middle Aged
• Ondansetron (therapeutic use)
• Postoperative Nausea and Vomiting (prevention & control)
• Severity of Illness Index
• Treatment Outcome